BioSpace News Archive

HOOKIPA Pharma Inc. today announced that the company will participate in the virtual SVB Securities Global Biopharma Conference, February 14 - 16, 2023.

Outlook Therapeutics, Inc. today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 4:20 PM ET.

Catalyst Pharmaceuticals, Inc., today provided preliminary 2022 fourth quarter and full year total revenues estimates, a forecast of 2023 total revenue expectations, and a corporate update.

Replimune Group, Inc. today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET.

Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the addition of Morristown Medical Center, part of the Atlantic Health System, as a new clinical trial site for INDP-D101

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 3:00 p.m. ET.

Axsome Therapeutics, Inc. today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, Feb. 15, 2023, at 8:40 a.m. Eastern Time.

Clearside Biomedical, Inc. announced today that data from the Company’s OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) will be presented at the following medical meetings in February 2023.

Anavex Life Sciences Corp. today reported financial results for its fiscal quarter ended December 31, 2022.

Nykode Therapeutics ASA today announced that its Chief Executive Officer, Michael Engsig, will present and host 1x1 meetings at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023, at 8:00 a.m. ET / 2:00 p.m. CET.